Novaerus Defend 1050 Proven to Reduce SARS-CoV-2 by 99.99% -- COMPAMED Trade Fair


Analis sa/nv

Novaerus Defend 1050 Proven to Reduce SARS-CoV-2 by 99.99%

“To successfully control the spread of pathogens and viruses, we need to close the infection control loop; hands, surfaces and air.” Dr Kevin Devlin, CEO at WellAir, the parent company of Novaerus.

Research suggest that disinfecting air plays a role in preventing the spread of SARS-CoV-2. While respiratory droplets are considered the primary transmission route, aerosols are being considered by many health authorities as a possible mode of infection transmission. This is also published in a recent paper by a Dutch group in the The Lancet Respiratory Medicine.

The air dis-infection device the Novaerus Defend 1050 has been independently tested and shown effective at reducing MS2 Bacteriophage, a surrogate for SARS-CoV-2, by 99.99% in 15 minutes. This is the conclusion from the Aerosol Research and Engineering (ARE) Laboratories. 

The Novaerus Defend 1050 combines rapid air dis-infection and purification into one device. It uses a patented ultra-low energy plasma technology combined with a triple-stage filtration system from Camfil®.  This is a non-selective, rapid killing technology, it offers a unique and safe solution to kill airborne viruses 24/7, reducing the risk of disease and infectious outbreaks.

Analis is the BeNeLux partner for Novaerus air disinfection devices. More information on

Exhibitor Data Sheet